Spero Therapeutics, Inc. Capital Expenditures
Spero Therapeutics, Inc. (SPRO) reported Capital Expenditures of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2021-11-10
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2020-12-31 was $12.00K, a 90.70% decline year-over-year.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2020-09-30 was $51.00K, a 200.00% increase year-over-year.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2020-06-30 was $15.00K, a 82.76% decline year-over-year.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2020 was $157.00K, a 50.00% decline from fiscal 2019.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2019 was $314.00K, a 87.11% decline from fiscal 2018.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2018 was $2.44M, a 8922.22% increase from fiscal 2017.
- Spero Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2017 was $27.00K, a 96.75% decline from fiscal 2016.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $63.00K derived: sum of 2 quarters · filed 2021-11-10 | $78.00K derived: sum of 3 quarters · filed 2021-11-10 | $157.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $66.00K derived: sum of 2 quarters · filed 2021-11-10 | $145.00K 10-Q · filed 2021-11-10 | $274.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $94.00K 10-Q · filed 2021-08-05 | $223.00K derived: sum of 3 quarters · filed 2021-08-05 | $240.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $79.00K 10-Q · filed 2021-05-06 | $208.00K derived: sum of 2 quarters · filed 2021-05-06 | $225.00K derived: sum of 3 quarters · filed 2021-05-06 | $312.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $146.00K derived: sum of 2 quarters · filed 2021-03-11 | $233.00K derived: sum of 3 quarters · filed 2021-03-11 | $314.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $104.00K derived: sum of 2 quarters · filed 2020-11-05 | $185.00K 10-Q · filed 2020-11-05 | $2.60M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $168.00K 10-Q · filed 2020-08-06 | $2.58M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | $81.00K 10-Q · filed 2020-05-08 | $2.50M derived: sum of 2 quarters · filed 2020-05-08 | ||
| 2018-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $2.44M 10-K · filed 2020-03-16 | ||
| 2018-09-30 | $22.00K 10-Q · filed 2019-11-04 | |||
| 2017-12-31 | $27.00K 10-K · filed 2019-03-14 | |||
| 2016-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $830.00K 10-K · filed 2019-03-14 | ||
| 2016-09-30 | $569.00K 10-Q · filed 2017-12-14 | |||
| 2015-12-31 | $232.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |